New drug cocktail aims to shrink brain tumors in lymphoma patients
NCT ID NCT07185373
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times
Summary
This study tests whether adding the targeted drug orelabrutinib to standard chemotherapy can improve outcomes for people newly diagnosed with primary central nervous system lymphoma (PCNSL), a rare brain cancer. About 215 adults will be randomly assigned to one of three treatment groups to compare how well the tumors shrink. The goal is to see if the new combination leads to more complete remissions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology, Qilu Hospital of Shandong University
Jinan, China
Contact
-
West China Hospital of Sichuan University
Chengdu, China
Contact
Conditions
Explore the condition pages connected to this study.